Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 8/20 | 0.80 |
| ▸ | TYK2 | P29597 | 6/20 | 0.52 |
| ▸ | JAK2 | O60674 | 4/20 | 0.52 |
| ▸ | JAK1 | P23458 | 3/20 | 0.52 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.48 |
| ▸ | SMO | Q99835 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.45 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30436545 | 1.00 | PPARG (0.80) | PPARGTYK2JAK2JAK1LRRK2 | |
| SCHEMBL21061956 | 0.93 | PPARG (0.89) | PPARGTYK2JAK2JAK1LRRK2 | |
| SCHEMBL21055970 | 0.91 | PPARG (0.82) | PPARGSMOGRM4 | |
| SCHEMBL30436926 | 0.91 | PPARG (0.82) | PPARGSMOGRM4 | |
| SCHEMBL21056010 | 0.89 | PPARG (1.00) | PPARGTYK2JAK2JAK1SMO | |
| SCHEMBL30437472 | 0.89 | PPARG (1.00) | PPARGTYK2JAK2JAK1SMO | |
| SCHEMBL30436764 | 0.88 | PPARG (1.00) | PPARG | |
| SCHEMBL21055968 | 0.88 | PPARG (1.00) | PPARG | |
| SCHEMBL21056004 | 0.87 | PPARG (0.67) | PPARGLRRK2GRM4 | |
| SCHEMBL30436815 | 0.87 | PPARG (0.67) | PPARGLRRK2GRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111630030-B | Novel benzamide derivatives as PPAR-gamma modulators | 梅迪比奥法尔玛公司 | 2023-06-20 | — | — | CN | claimed |
| US-11267808-B2 | Benzamide derivatives as PPAR-gamma modulators | MEDIBIOFARMA, S.L. (ES) | 2022-03-08 | — | — | US | claimed |
| EP-3724165-B1 | NEW BENZAMIDE DERIVATIVES AS PPAR-GAMMA MODULATORS | MEDIBIOFARMA S L (ES) | 2022-01-12 | — | — | EP | claimed |
| US-20210171511-A1 | NEW BENZAMIDE DERIVATIVES AS PPAR-GAMMA MODULATORS | MEDIBIOFARMA, S.L. (ES) | 2021-06-10 | — | — | US | claimed |
| EP-3724165-A1 | NEW BENZAMIDE DERIVATIVES AS PPAR-GAMMA MODULATORS | MEDIBIOFARMA, S.L. (ES) | 2020-10-21 | — | — | EP | claimed |
| CN-111630030-A | Novel benzamide derivatives as PPAR-gamma modulators | 梅迪比奥法尔玛公司 | 2020-09-04 | — | — | CN | claimed |
| WO-2019115498-A1 | NEW BENZAMIDE DERIVATIVES AS PPAR-GAMMA MODULATORS | MEDIBIOFARMA, S.L. (ES) | 2019-06-20 | — | — | WO | claimed |
| EP-3498694-A1 | NEW BENZAMIDE DERIVATIVES AS PPAR-GAMMA MODULATORS | MEDIBIOFARMA, S.L. (ES) | 2019-06-19 | — | — | EP | claimed |
| CN-111630030-B | Novel benzamide derivatives as PPAR-gamma modulators | 梅迪比奥法尔玛公司 | 2023-06-20 | — | — | CN | disclosed |
| US-11267808-B2 | Benzamide derivatives as PPAR-gamma modulators | MEDIBIOFARMA, S.L. (ES) | 2022-03-08 | — | — | US | disclosed |
| EP-3724165-B1 | NEW BENZAMIDE DERIVATIVES AS PPAR-GAMMA MODULATORS | MEDIBIOFARMA S L (ES) | 2022-01-12 | — | — | EP | disclosed |
| EP-3724165-B1 | NEW BENZAMIDE DERIVATIVES AS PPAR-GAMMA MODULATORS | MEDIBIOFARMA S L (ES) | 2022-01-12 | — | — | EP | disclosed |
| US-20210171511-A1 | NEW BENZAMIDE DERIVATIVES AS PPAR-GAMMA MODULATORS | MEDIBIOFARMA, S.L. (ES) | 2021-06-10 | — | — | US | disclosed |
| US-20210171511-A1 | NEW BENZAMIDE DERIVATIVES AS PPAR-GAMMA MODULATORS | MEDIBIOFARMA, S.L. (ES) | 2021-06-10 | — | — | US | disclosed |
| EP-3724165-A1 | NEW BENZAMIDE DERIVATIVES AS PPAR-GAMMA MODULATORS | MEDIBIOFARMA, S.L. (ES) | 2020-10-21 | — | — | EP | disclosed |
| CN-111630030-A | Novel benzamide derivatives as PPAR-gamma modulators | 梅迪比奥法尔玛公司 | 2020-09-04 | — | — | CN | disclosed |
| WO-2019115498-A1 | NEW BENZAMIDE DERIVATIVES AS PPAR-GAMMA MODULATORS | MEDIBIOFARMA, S.L. (ES) | 2019-06-20 | — | — | WO | disclosed |
| WO-2019115498-A1 | NEW BENZAMIDE DERIVATIVES AS PPAR-GAMMA MODULATORS | MEDIBIOFARMA, S.L. (ES) | 2019-06-20 | — | — | WO | disclosed |
| EP-3498694-A1 | NEW BENZAMIDE DERIVATIVES AS PPAR-GAMMA MODULATORS | MEDIBIOFARMA, S.L. (ES) | 2019-06-19 | — | — | EP | disclosed |
| EP-3498694-A1 | NEW BENZAMIDE DERIVATIVES AS PPAR-GAMMA MODULATORS | MEDIBIOFARMA, S.L. (ES) | 2019-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171511-A1 | NEW BENZAMIDE DERIVATIVES AS PPAR-GAMMA MODULATORS | PPARD, PPARG, PPARA | PPARG 2/4885TYK2 2578/4885JAK2 1458/4885 |
| US-11267808-B2 | Benzamide derivatives as PPAR-gamma modulators | PPARG, PPARD, PPARA | PPARG 1/4885TYK2 2825/4885JAK2 1359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.